ATR-12 is under clinical development by Azitra and currently in Phase I for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair). According to GlobalData, Phase I drugs for Netherton Syndrome (Trichorrhexis Invaginata, Bamboo Hair) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the ATR-12 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

ATR-12 overview

ATR-12 is under development for the treatment of Netherton’s syndrome. The drug candidate is a genetically modified organism (GMO) live biotherapeutic product comprising of Staphylococcus epidermidis (SE351 strain) engineered to express therapeutic levels of serine protease inhibitor Kazal-type 5 (LEKTI). The drug candidate is administered through topical route in the form of non-aqueous ointment. It is developed based on the microbiome dermatology platform. 

Azitra overview

Azitra is a synthetic biology company that discovers and develops novel formulations to treat adverse skin conditions and diseases. It is investigating ATR-04 cream for the treatment of cancer-therapy-associated rashes, ATR-12 a non-aqueous ointment against Netherton syndrome, ATR-0, a topical formulation for eczema and others. Azitra utilizes its microbiome dermatology platform to develop consumer and live biotherapeutic products (LBP’s). The company engineers commensal skin bacteria and delivers natural and disease-modifying proteins directly to the target area of the skin. Azitra is headquartered in Branford, Connecticut, the US.

For a complete picture of ATR-12’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.